THESE TEXTS ARE IN THE DUTCH LANGUAGE AND TAKE THIS SERIOUS !!!!!!
j
Dubois Barnett <duboisbarnett@gmail.com>
Fri, 25 Mar, 17:08
to volwassenen
Hieruit blijkt dat er opzettelijke schade word gedaan in plaats van geneesende kunde.
Ggznieuws.nl
14 juli 2020 – Een onderzoek van het Center for Addiction and Mental Health in Toronto, Canada.gepubliceerd in JAMA Psychiatry toont aan dat antipsychotica de hersenen kunnen beschadigen.
In de nieuwe studie blijkt het gebruik van antipsychotica (in dit geval olanzapine) gelinkt aan schade aan de hersenen. De onderzoekers gebruikten een gerandomiseerd, gecontroleerd onderzoek waarmee ze konden aantonen dat de medicijnen het waargenomen effect op de hersenen veroorzaakten. De onderzoekers vonden corticale verdunning bij de personen die de antipsychotica gebruikten vergeleken met degenen die een placebo namen.
“In tegenstelling tot ongecontroleerde studies, biedt ons gerandomiseerde, dubbelblinde, placebo gecontroleerde ontwerp van deze klinische studie het potentieel bewijs voor oorzakelijk verband: toediening van olanzapine kan bij mensen een versnelde afname van de corticale dikte veroorzaken”, schrijven de onderzoekers.
Blootstelling aan olanzapine gedurende slechts 36 weken resulteerde in een verlies van corticale dikte dat gelijk is aan vier keer het verlies over de gehele levensduur van iemand die het medicijn niet heeft gebruikt.
Er zijn ook goede resultaten te zien bij degenen die stoppen met het gebruik van antipsychotica. Een recent onderzoek toont aan dat het toevoegen van antipsychotica aan psychotherapie voor psychose in de eerste episode niet tot enige verbetering leidt. Het stoppen van het gebruik van antipsychotica wordt ook in verband gebracht met verbetering van de cognitieve functies.
NB : Het advies blijft om een actieve psychose met antipsychotica te behandelen. Een psychose veroorzaakt dezelfde nadelige veranderingen van de hersenschors als olanzapine. Het is wel aan te raden antipsychotica echt alleen voor behandeling van psychoses voor te schrijven.
Resultaten
Bij het vergelijken van degenen die olanzapine gebruikten met die op placebo, hadden degenen in de olanzapinegroep meer corticale verdunning – wat betekent dat het medicijn daarvoor verantwoordelijk was.
De onderzoekers merken op dat antipsychotica steeds vaker worden voorgeschreven aan mensen met diagnoses als autisme en depressie. Ze bevestigen ook dat antipsychotica tal van gevaarlijke bijwerkingen met zich meebrengen, waaronder niet in de laatste plaats het risico op plotseling overlijden – ‘met een risico op onverwacht overlijden aanzienlijk hoger bij zowel kinderen als oudere personen’.
De onderzoekers bevestigden dat in dit onderzoek de aangetoonde effecten van olanzapine op de hersenstructuur met name bij oudere deelnemers meer uitgesproken waren.
Voineskos, A. N., Mulsant, B. H., Dickie, E. W., Neufeld, N. H., Rothschild, A. J., Whyte, E. M., Flint, A. J. (2020). Effects of antipsychotic medication on brain structure in patients with major depressive disorder and psychotic features: Neuroimaging findings in the context of a randomized placebo-controlled clinical trial. JAMA Psychiatry. Published online, February 26, 2020. DOI: 10.1001/jamapsychiatry.2020.0036. JAMA Psychiatry
Rxlist.com
What Are Side Effects Associated with Using Olanzapine?
Side effects of olanzapine include:
• Dizziness/low blood pressure upon standing
• Weight gain, dose dependent
• High levels of triglycerides in the blood
• High cholesterol
• Drowsiness, dose dependent
• Extrapyramidal symptoms (EPS), dose dependent (muscle spasms, jerky movements, slow movements)
• Dry mouth
• Weakness
• Dizziness
• Accidental injury
• Insomnia
• Elevated alanine aminotransferase (ALT) level
• Constipation
• Indigestion
• Elevated levels of prolactin in the blood
• High blood sugar
• Low blood pressure
• Tremor
• Weakness
• Restlessness
• Parkinsonism reactions
This document does not contain all possible side effects and others may occur. Check with your physician for additional information about side effects.
What Other Drugs Interact with Olanzapine?
If your doctor has directed you to use this medication, your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring you for them. Do not start, stop, or change the dosage of any medicine before checking with your doctor, health care provider or pharmacist first.
Severe interactions of olanzapine include:
There are no known severe reactions from the use of olanzapine.
Serious interactions of olanzapine include:
• apomorphine
• bromocriptine
• cabergoline
• dopamine
• fluvoxamine
• levodopa
• lisuride
• mefloquine
• methyldopa
• ondansetron
• pefloxacin
• pramipexole
• ropinirole
• sodium oxybate
• umeclidinium bromide/vilanterol inhaled
• vilanterol/fluticasone furoate inhaled
Moderate interactions:
Olanzapine has known moderate interactions with at least 293 different drugs.
Mild interactions:
• brimonidine
• chasteberry
• ethanol
• eucalyptus
• omeprazole
• ruxolitinib
• sage
This document does not contain all possible interactions. Therefore, before using this product, tell your doctor or pharmacist of all the products you use. Keep a list of all your medications with you, and share the list with your doctor and pharmacist. Check with your physician if you have health questions or concerns.
What Are Warnings and Precautions for Olanzapine?
Warnings
Not approved for dementia-related psychosis; elderly patients with dementia-related psychosis who are treated with antipsychotic drugs are at increased risk of death, as shown in short-term controlled trials; in these trials, deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.
Patients are at risk for severe sedation (including coma) or delirium after each injection and must be observed for at least 3 hours in registered facility with ready access to emergency response services.
This medication contains olanzapine. Do not take Zyprexa, Zyprexa Relprevv, or Zyprexa Zydis if you are allergic to olanzapine or any ingredients contained in this drug.
Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center immediately.
Contraindications
Documented hypersensitivity
Effects of Drug Abuse
No information available
Short-Term Effects
No information available
Long-Term Effects
No information available
Cautions
Increased risk of hyperglycemia and diabetes; in some cases, hyperglycemia concomitant with use of atypical antipsychotics has been associated with ketoacidosis, hyperosmolar coma, or death.
Monitor blood glucose of high-risk patients.
Irreversible, involuntary, dyskinetic movements may develop with antipsychotic drugs; prevalence appears to be highest among elderly individuals, especially elderly women; discontinue if clinically appropriate.
May cause anticholinergic effects including paralytic ileus, urinary retention, xerostomia, BPH, and visual problems.
Neutropenia, leukopenia, and agranulocytosis reported; discontinue therapy at firs sign of blood dyscrasias or if absolute neutrophil count less than 1000/mm³.
Cerebrovascular effects including, stroke and transient ischemic attack resulting in death reported.
NMS has been reported.
Increased potential for weight gain; patients should receive regular monitoring of weight.
Appropriate clinical monitoring is recommended, including fasting blood lipid testing at the beginning of, and periodically during, treatment.
May elevate prolactin levels.
May induce orthostatic hypotension associated with dizziness, tachycardia, bradycardia and, in some patients, syncope, especially during initial dose-titration period, probably as consequence of alpha1-adrenergic antagonistic properties.
Do not reconstitute with lorazepam injection; do not mix with diazepam or haloperidol in syringe.
FDA warning regarding off-label use for dementia in elderly.
In narrow-angle glaucoma, cardiovascular dis ease, cerebrovascular disease, prostatic hypertrophy, hypovolemia, and dehydration, hyperglycemia may occur and in some cases may be extreme, resulting in ketoacidosis, hyperosmolar coma, or death; IM administration of greater than 1 injection is associated with substantial orthostatic hypotension (33%); maintain patient in recumbent position and monitor blood pressure before repeating IM doses.
Use caution in patients with history of seizures or with conditions that potentially lower seizure threshold.
Changes from normal to high prolactin levels observed in controlled studies (incidence, 30%).
Use caution in patients at risk of pneumonia; may cause esophageal dysmotility and aspiration.
Use caution with strenuous exercise, dehydration, heat exposure, and medications with anticholinergic effects; impaired core body temperature regulation may occur.
Increased potential (in adolescents as compared with adults) for weight gain and hyperlipidemia; clinicians prescribing to adolescents should consider potential long-term risks, which in many cases may lead them to prescription of other drugs first in this population.
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) reported with olanzapine exposure; DRESS may present with a cutaneous reaction (such as rash or exfoliative dermatitis), eosinophilia, fever, and/or lymphadenopathy with systemic complications such as hepatitis, nephritis, pneumonitis, myocarditis, and/or pericarditis; DRESS is sometimes fatal; discontinue olanzapine if DRESS suspected.
Possibility of suicide attempt is inherent in schizophrenia and in bipolar I disorder, and close supervision of high-risk patients should accompany drug therapy; when using in combination with fluoxetine, also refer to Boxed
Warning and Precautions sections of package insert for Symbyax.
A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) reported; management of NMS should include: 1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; 2) intensive symptomatic treatment and medical monitoring; and 3) treatment of any concomitant serious medical problems for which specific treatments are available; there is no general agreement about specific pharmacological treatment regimens for NMS; if patient requires antipsychotic drug treatment after recovery from NMS, potential reintroduction of drug therapy should be carefully considered; patient should be carefully monitored, since recurrences of NMS reported.
Has potential to impair judgment, thinking, and motor skills; use caution when operating machinery.
Olanzapine indicated as integral part of comprehensive treatment program for pediatric patients with schizophrenia and bipolar disorder, which may include other measures (e.g., psychological, educational, social) as well.
No comments:
Post a Comment